Left Menu
Development News Edition

Encouraging Oxford vaccine results keep Britain on track for spring roll-out

Reuters | Washington DC | Updated: 23-11-2020 22:29 IST | Created: 23-11-2020 22:23 IST
Encouraging Oxford vaccine results keep Britain on track for spring roll-out
Representatve image Image Credit: ANI

Britain is on track to make COVID-19 vaccines widely available by next spring after the shot developed by Oxford University and AstraZeneca was up to 90% effective in trials, the head of the university's Jenner Institute told Reuters on Monday. The encouraging late-stage interim trial results were the third set of data showing efficacy levels among the seven vaccine candidates Britain has ordered, after Pfizer/BioNTech and Moderna earlier this month.

"I think we are on track for the timeline ... to start getting this vaccine rolled out from December," Adrian Hill, director of Oxford University's Jenner Institute that developed the vaccine, told Reuters. Britain has secured 100 million doses of the AstraZeneca shot, 40 million of the Pfizer vaccine and 5 million of Moderna's candidate.

British Prime Minister Boris Johnson has highlighted the prospect of vaccines as a reason for optimism that things could improve by spring after he introduced a second national lockdown in England this month to tackle rising infections. "Clearly the most hopeful advance of all is how vaccines are now edging ever closer to liberating us from the virus, demonstrating emphatically that this is not a pandemic without end," he told parliament on Monday.

"We can take great heart from today's news, which has the makings of a wonderful British scientific achievement." AstraZeneca's interim results showed that a regimen of two full doses was 62% effective in shielding people from COVID-19, though the efficacy rate jumped to 90% if the first shot was only half a normal dose.

Hill said high-risk groups would receive the AstraZeneca vaccine before it was rolled out to everyone in spring. "I think that could be done. It's going to be an enormous effort ... hopefully there will be vaccine available for all adults, but that's likely to be springtime rather than in January," Hill said.

BACK TO NORMAL? AstraZeneca executive Pam Cheng said there would be enough supplies of the active ingredient in the vaccine to provide Britain with 20 million doses by the end of the year and 70 million by the end of March.

She said that would translate into 4 million finished doses this year and 40 million by the end of March. The vaccine is also being manufactured by other AstraZeneca partners. Britain's health minister has asked the health service to be prepared to deliver vaccines from Dec. 1, although he said he expects the bulk of the roll-out to happen next year.

"It's marvellous," said 59-year-old Jo Canilleri. "Hopefully we won't take that long before we can actually get it, because ... a lot of people are just ignoring this. It's not a thing that you can ignore. I mean look at the lives we've lost." In Britain 55,000 people have died from COVID-19, the highest death toll in Europe.

Britain expects to receive 10 million doses of the Pfizer vaccine, which was 95% effective in trials, this year but the fact it needs to be stored at minus 70 degrees Celsius could pose logistical challenges for a mass roll-out. Britain won't receive any Moderna vaccines, which were 94.5% effective based on initial results, until next spring.

Andrew Pollard, director of the Oxford Vaccine Group and chief investigator into the trial, said results released so far showed vaccines could help protect against severe cases, which in turn would help Britain's National Health Service (NHS). "That, to me, means that, whichever of the vaccines we could deploy we're likely to be able to prevent people going into hospital clogging up, in this country, the NHS and allow us to at least get that bit of the system back to normal," he told Reuters.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

China: A savior for emerging markets or a poison pill?

... ...

Future of Urban Planning: Artificial Intelligence guiding the way

Advances in emerging technologies like Artificial Intelligence and Machine Learning can help us understand our cities better and derive useful insights from real-time data collected through automated models....

Videos

Latest News

Reuters US Domestic News Summary

Following is a summary of current US domestic news briefs. Baked Alaska arrested in Capitol Hill riot FBIFar-right media personality Tim Gionet, who goes by the handle Baked Alaska, was arrested on Friday by the Federal Bureau of Investigat...

Reuters World News Summary

Following is a summary of current world news briefs. End of Merkel era begins as German CDU picks new party leaderGermanys Christian Democrats elect a new chairman on Saturday, aiming to unite their conservative party behind a new leader wh...

Reuters Sports News Summary

Following is a summary of current sports news briefs. Sherpas successfully complete first winter summit of K2 Spanish climber killedA team of climbers from Nepal on Saturday become the first mountaineers to successfully complete a winter at...

Tennis-Andreescu's coach tests positive for COVID-19 ahead of Australian Open

Sylvain Bruneau, the coach of 2019 U.S. Open champion Bianca Andreescu, said on Saturday he has tested positive for COVID-19 after arriving in Melbourne ahead of next months Australian Open. Bruneau said in a statement shared by Tennis Cana...

Give Feedback